Anvisa Approves New Indications for Medication that Treats Breast Cancer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.10 Articles
10 Articles
Forbes, the world's most well-conceived business and economic magazine. Drug is used in adult patients with triple-negative type The post Anvisa Approves New Indications for Remedy Treating Breast Cancer apareceu primeiro em Forbes Brasil.
Use of Trodelvy is to treat triple-negative breast cancer, more aggressive and with fewer therapeutic options The post Anvisa approves new treatments with medication for breast cancer apareceu primeiro em AMAZONAS CURUAL.
Trodelvy begins to have two new indications for patients with advanced disease, including use in combination with pembrolizumab
Tribuna Online
The National Health Surveillance Agency (Anvisa) approved new therapeutic indications for Trodelvy (sacituzumab govitecana), used in the treatment of adult patients with triple-negative breast cancer (MCTN).
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
